Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer (Q38062459)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

1 reference

Europe PubMed Central

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Jean-Charles Soria

1

object named as

J-C Soria

0 references

author name string

J-C Soria

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

M Reck

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

A B Sandler

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

N Saijo

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

D H Johnson

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

D Burcoveanu

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

M Fukuoka

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

B Besse

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

J-P Pignon

10

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

meta-analysis of bevacizumab in advanced NSCLC collaborative group

11

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

23 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

20-30

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Publication bias and dissemination of clinical research.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Bevacizumab increases risk for severe proteinuria in cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Meta-analysis when only the median survival times are known: a comparison with individual patient data results

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Meta-analysis of chemotherapy in head and neck cancer: individual patient data vs literature data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Meta-analysis of individual participant data: rationale, conduct, and reporting

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS590

21 January 2018

Identifiers

10.1093/ANNONC/MDS590

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38062459&oldid=1966790220"